Breaking news

UAE’s K2 Think Emerges as a Formidable Contender in Global AI

Introduction

The global artificial intelligence landscape has welcomed a new challenger. The Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) in the United Arab Emirates has unveiled K2 Think, a low-cost reasoning model designed to compete with industry heavyweights such as OpenAI and DeepSeek.

Innovative Design With Fewer Parameters

Unlike its competitors, K2 Think is built on only 32 billion parameters. Derived from Alibaba’s open-source Qwen 2.5 model and powered by hardware from AI chipmaker Cerebas, this model delivers performance on par with far larger systems. In comparison, DeepSeek’s R1 model contains an astonishing 671 billion parameters, underscoring the efficiency of K2 Think.

Advanced Techniques Driving Performance

The team at MBZUAI, in collaboration with UAE-based AI firm G42 and backed by Microsoft, credits the breakthrough to a combination of advanced methodologies. Techniques such as long chain-of-thought supervised fine-tuning and test-time scaling have ensured robust performance. As Hector Liu, director of MBZUAI’s Institute of Foundation Models, explains, the model was developed as an evolving system rather than a static release, a strategy that continuously refines its capabilities.

Geopolitical and Industry Implications

While the AI race has traditionally been dominated by U.S. and Chinese players, K2 Think marks a significant step for the UAE in diversifying its technological influence beyond simple energy economics. This move not only reinforces the UAE’s ambitions in digital innovation but also introduces a new element to the broader geopolitical contest for AI supremacy.

Focused Applications Across Science and Technology

Rather than serving as a generic chatbot, K2 Think targets specific applications in fields such as mathematics and science. Richard Morton, managing director for MBZUAI’s Institute of Foundation Models, argues that the model’s ability to mimic foundational human reasoning can dramatically condense processes that previously took years to complete. This efficiency could potentially democratize access to advanced AI technologies in regions lacking the deep pockets and infrastructure of U.S. tech giants.

Conclusion

K2 Think represents both a technological and strategic leap. By achieving high performance with a fraction of the parameters used by its rivals, MBZUAI has demonstrated that cutting-edge artificial intelligence does not always require the largest scale. As the AI landscape evolves, innovations like these will continue to reshape industry dynamics and geopolitical power structures around the globe.

Cyprus-based MammoCheck Wins Top Honour At NBG Business Seeds Competition

Cyprus-based medical technology startup MammoCheck has won first place at the 16th NBG Business Seeds Innovation and Technology Competition, emerging as the overall winner from 344 entries submitted from Greece, Cyprus and other countries.

The annual competition, organised by the National Bank of Greece, announced the results during an awards ceremony in Athens. MammoCheck received the competition’s top distinction along with a €20,000 cash prize.

Founded in 2024 as a spin-out from Frederick University, MammoCheck is developing an artificial intelligence-powered Software as a Medical Device (SaMD) platform designed to support breast cancer screening. The solution combines a smartphone application with low-cost thermal cameras to provide an adjunctive screening tool powered by AI.

The company says its technology aims to address a significant gap in breast cancer screening, with hundreds of millions of women worldwide lacking regular access to mammography, including many women under the age of 45 who are not covered by most national screening programmes.

“We are honoured to receive first place among 344 entries from Greece, Cyprus and abroad. This recognition reflects the dedication of our team, our clinical partners and the women who inspire our work every day,”

said Alexandra Dimitriadou, co-founder and CEO of MammoCheck.

MammoCheck is currently conducting a clinical trial across multiple hospital sites as it advances toward FDA 510(k) clearance in the United States and CE marking under the European Union’s Medical Device Regulation (MDR).

The latest award marks another milestone for Cyprus’ growing health technology ecosystem, highlighting the increasing international visibility of locally developed medical innovations.

The Future Forbes Realty Global Properties
eCredo
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter